News

Amgen Inc. (NASDAQ:AMGN) ranks among the best set-it-and-forget-it stocks to buy. On June 24, Piper Sandler reaffirmed its ...
Amgen Inc. (NASDAQ:AMGN) is one of the 10 Best Value Stocks to Buy According to Billionaires. On June 23, the company ...
Eli Lilly and Novo Nordisk, which already have approved GLP-1 weight loss drugs that are raking in billions of revenues, have ...
Amgen's long-acting experimental obesity drug MariTide needs to be given at a low starting dose to limit side effects like ...
Having to take Ozempic or other weight loss drugs can be a real pain in the ass, with users often having to jab themselves ...
Amgen shares are trading lower Monday afternoon. The company released full results from part one of its phase two study of ...
While Amgen’s monthly obesity candidate MariTide helped patients lose significant amounts of weight in a phase 2 study, ...
Amgen plans to proceed with Phase 3 trials, initiating patients on a lower dosage that will gradually increase over an ...
Full Phase 2 study results showed side effects that led people to stop treatment with MariTide, as well as weight loss ...
Amgen's weight-loss drug MariTide had a successful Phase 2 trial so the company is expanding development plans to study its use for heart disease and sleep apnea.
Amgen's experimental drug MariTide shows potential for significant weight loss in obese patients, despite notable side ...
MariTide helped participants lose up to 20% of their body weight in a year-long trial. But it could be years before the new ...